Chipping in on clonal hematopoiesis

Por Gillis, Nancy K., Padron, Eric
Publicado no Oncotarget (2017)

The pharmacogenomics of drug resistance to protein kinase inhibitors

Por Gillis, Nancy K., McLeod, Howard L.
Publicado no Drug Resist Updat (2016)

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein

Por Gillis, Nancy K, Zhu, Hao-Jie, Markowitz, John S
Publicado em 2011

Clinical Implementation of Germline Cancer Pharmacogenetic Variants during the Next-Generation Sequencing Era

Por Gillis, Nancy K., Patel, Jai N., Innocenti, Federico
Publicado em 2013

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience

Por Knepper, Todd C., Bell, Gillian C., Hicks, J. Kevin, Padron, Eric, Teer, Jamie K., Vo, Teresa T., Gillis, Nancy K., Mason, Neil T., McLeod, Howard L., Walko, Christine M.
Publicado no Oncologist (2017)

Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors

Por Gillis, Nancy K., Rotroff, Daniel M., Mesa, Tania E., Yao, Jiqiang, Chen, Zhihua, Carulli, Michael A., Yoder, Sean J., Walko, Christine M., Teer, Jamie K., McLeod, Howard L.
Publicado no Oncotarget (2017)

Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study

Por McDonough, Caitrin W., Gillis, Nancy K., Alsultan, Abdullah, Chang, Shin-Wen, Kawaguchi-Suzuki, Marina, Lang, Jason E., Shahin, Mohamed Hossam A., Buford, Thomas W., El Rouby, Nihal M., Sá, Ana C.C., Langaee, Taimour Y., Gums, John G., Chapman, Arlene B., Cooper-DeHoff, Rhonda M., Turner, Stephen T., Gong, Yan, Johnson, Julie A.
Publicado em 2013